1. Home
  2. CSBR vs MOLN Comparison

CSBR vs MOLN Comparison

Compare CSBR & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CSBR
  • MOLN
  • Stock Information
  • Founded
  • CSBR 1985
  • MOLN 2004
  • Country
  • CSBR United States
  • MOLN Switzerland
  • Employees
  • CSBR N/A
  • MOLN N/A
  • Industry
  • CSBR Biotechnology: Biological Products (No Diagnostic Substances)
  • MOLN
  • Sector
  • CSBR Health Care
  • MOLN
  • Exchange
  • CSBR Nasdaq
  • MOLN Nasdaq
  • Market Cap
  • CSBR 123.2M
  • MOLN 142.6M
  • IPO Year
  • CSBR 1986
  • MOLN 2021
  • Fundamental
  • Price
  • CSBR $6.75
  • MOLN $3.53
  • Analyst Decision
  • CSBR Strong Buy
  • MOLN
  • Analyst Count
  • CSBR 1
  • MOLN 0
  • Target Price
  • CSBR $12.00
  • MOLN N/A
  • AVG Volume (30 Days)
  • CSBR 39.7K
  • MOLN 1.1K
  • Earning Date
  • CSBR 09-10-2025
  • MOLN 08-25-2025
  • Dividend Yield
  • CSBR N/A
  • MOLN N/A
  • EPS Growth
  • CSBR N/A
  • MOLN N/A
  • EPS
  • CSBR 0.33
  • MOLN N/A
  • Revenue
  • CSBR $56,944,000.00
  • MOLN $2,525,030.00
  • Revenue This Year
  • CSBR $9.30
  • MOLN N/A
  • Revenue Next Year
  • CSBR $31.17
  • MOLN $1,000.00
  • P/E Ratio
  • CSBR $19.52
  • MOLN N/A
  • Revenue Growth
  • CSBR 13.54
  • MOLN N/A
  • 52 Week Low
  • CSBR $3.60
  • MOLN $3.36
  • 52 Week High
  • CSBR $11.99
  • MOLN $7.60
  • Technical
  • Relative Strength Index (RSI)
  • CSBR 41.70
  • MOLN 41.49
  • Support Level
  • CSBR $5.85
  • MOLN $3.41
  • Resistance Level
  • CSBR $6.74
  • MOLN $3.96
  • Average True Range (ATR)
  • CSBR 0.54
  • MOLN 0.08
  • MACD
  • CSBR -0.14
  • MOLN -0.02
  • Stochastic Oscillator
  • CSBR 26.08
  • MOLN 20.34

About CSBR Champions Oncology Inc.

Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Share on Social Networks: